Conference Report

Conference Report From the 2008 Gastrointestinal Cancers Symposium: Esophageal and Gastric Cancers

Source: CCO Independent Conference Coverage of the 2008 Gastrointestinal Cancers Symposium*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Conference Report From the 2008 Gastrointestinal Cancers Symposium: Esophageal and Gastric Cancers


Faculty:

Peter C. Enzinger, MDDavid H. Ilson, MD, PhD
  • Peter C. Enzinger, MD
  • David H. Ilson, MD, PhD

CME CREDIT INFORMATION

Release Date: 04/07/08

Expiration Date: 04/06/09


Physicians: maximum of 1.0 AMA PRA Category 1 Credit™

Status: Please log in to view status

Begin the Conference Report

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Summarize recent clinical trial data regarding preoperative chemotherapy in esophageal cancer
  • Identify key issues in interpretation of recent trial data on cetuximab in advanced esophageal cancer
  • Describe recent clinical trial results relating to adjuvant chemotherapy of patients with gastric cancer in the context of current American and European practice patterns in these patients
  • Explain the clinical implications of interpatient variability in the pharmacokinetic profile of imatinib in patients with gastrointestinal stromal tumors

Topics covered include:

  • Overview
  • Preoperative Chemotherapy in Esophageal Cancer: Modest Improvement
  • Cetuximab in Advanced Esophageal Cancer: Differing Views on SWOG Phase II Data
  • Posttreatment PET Scanning in Locally Advanced Esophageal Cancer: Does It Improve Diagnosis?
  • Metabolic Syndrome as a Risk Factor for Barrett’s Esophagus
  • Adjuvant Chemotherapy for Gastric Cancer: More Data for the Debate
  • S-1 Plus Irinotecan in Advanced Gastric Cancer: Phase III Trial Results
  • Adjuvant Imatinib in Gastrointestinal Stromal Tumors: Survival Benefits
  • Imatinib Exposure and Outcomes in Patients With Unresectable GIST
  • Sorafenib in Imatinib- and Sunitinib-Resistant GIST: Early Results
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.

Contact Info

Educational grants provided by:

Educational grants support only the CME-certified components of this program.